Back to search results

BRANCH-HF Study: Learning About PF-07328948 for Heart Failure

This study, called BRANCH-HF, is looking into a medicine called PF-07328948 for adults with heart failure. The goal is to understand how safe PF-07328948 is and how well it works compared to a placebo (an inactive pill). You might be able to join if you are 18 to 79 years old, have had heart failure for at least 3 months, and meet other specific health criteria, including your heart's pumping ability (left ventricular ejection fraction greater than 40%). The study will measure how many participants experience certain health events, changes in walking distance (6-Minute Walk Test), and improvements in heart failure symptoms (Kansas City Cardiomyopathy Questionnaire Overall Total Symptom Score) over 36 weeks. The study is currently recruiting about 620 participants.

Study design
This interventional study will involve 620 participants who will receive either PF-07328948 at different doses or a placebo. It is designed to compare the effects of the study medicine to a placebo.
What's involved
You would take a tablet once daily for 36 weeks. You will be involved in the study for about 48 weeks, with 15 clinic visits, 5 of which may be by phone and 10 at the study site.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured at 36 weeks post-dose, and participants are involved for about 48 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06991257

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Recruiting
PHASE2Ages 18–79InterventionalTreatment
Pfizer
~620 participants
Updated 2026-05-27 on ClinicalTrials.gov
What's tested:PlaceboLow Dose PF-07328948Medium Dose PF-07328948High Dose PF-07328948

At a glance

Recruiting sites
132 of 142 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Clinical Events
Measured over over 36 weeks
+2 more outcomes measured

Conditions

Heart Failure

Explore related trials

Heart FailureHeart failure with normal ejection fraction

Where it's being run

142 sites across 73 states
Bulgaria8
Illinois7
Florida6
Ontario6
Quebec6
Czechia6
Hungary5
Tokyo5

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

aged 18 years to \< 80 years
clinically confirmed to have a diagnosis of heart failure for at least 3 months
New York Heart Association Class II-IV symptoms
left ventricular ejection fraction greater than 40%
Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score \< 85
Six-minute walking distance greater than 75 meters

Exclusion

Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body.
Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor.
History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes
Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor

What this trial measures

  • Number of Participants with Clinical Eventsover 36 weeks

    Adjudicated cardiovascular death and worsening heart failure events through 36 weeks.

  • Change From Baseline in 6-Minute Walk Test (6MWD)Baseline, week 36 post-dose

    A submaximal exercise test that measures the distance the participant can walk within prescribed time of 6 minutes. Participants are asked to perform the test at a pace comfortable to them with as many breaks as needed. The total distance walked is recorded.

  • Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Total Symptom Score (KCCQ-23 TSS)Baseline, week 36

    KCCQ is a 23-item heart-failure specific questionnaire quantified into the following scores: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life, and self-efficacy, total symptom score, overall summary score, and clinical summary score. To facilitate interpretation, all scores are presented on a scale of 0 to 100 points, with lower scores indicating more severe symptoms and/or limitations, and a score of 100 indicating no symptoms, no limitations, and excellent quality of life.